CytomX expects cash runway to at least the second half of 2028 as Varseta-M targets a first half of 2027 registrational study

Q1 2026 Management View Dr. Sean McCarthy framed 2026 as “a transformational year for CytomX,” citing “excellent clinical progress with Varseta-M in late line colorectal cancer” and positioning ...

CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates

Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline ...

CG Oncology Inc.: CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates

Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuva ...
Microsoft

When prompts become shells: RCE vulnerabilities in AI agent frameworks

New research exposes how prompt injection in AI agent frameworks can lead to remote code execution. Learn how these ...